Metachromatic Leukodystrophy Clinical Trial
— AzylisOfficial title:
and Safety of METAZYM (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile MLD Who Had Previously Hematopoietic Stem Cell Transplantation
Verified date | February 2011 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
There is currently no effective treatment for late infantile MLD once clinical symptoms are evident. METAZYM is a recombinant human arylsulfatase A developed for an intravenous ERT for the treatment of late infantile MLD. The overall objective of this study is to evaluate the efficacy and safety of intravenous rhASA treatment in a patient with late infantile MLD who had previously received hematopoietic stem cell transplantation (HCT).
Status | Completed |
Enrollment | 1 |
Est. completion date | April 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months and older |
Eligibility |
Inclusion Criteria: - Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities. - The patient must have a confirmed diagnosis of MLD as defined by:ARSA activity < 10 nmol/h/mg in leukocytes prior to HCT; Presence of elevated sulfatide in urine prior to HCT - The patient must have a residual level of voluntary function (as judged by the investigator), including presence of residual cognitive function (attention, executive and visual functions) as well as the presence of residual voluntary motor function in one upper or lower limb as a minimum. - The patient must have an age at the time of screening = 6 months - The patient must have had onset of symptoms before the age of 4 years - The subject and his/her guardian(s) must have the ability to comply with the clinical protocol - The patients' medical record must document that the legal guardian(s) has had independent counselling or a consultation regarding stem cell transplantation in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative Exclusion Criteria: Patient will be excluded from this study if they do not meet the specific inclusion criteria, or if any of the following criteria apply: - Presence of a gross motor function measure (GMFM < 25) - Presence of severe pseudo-bulbar signs (weakness and disco-ordination of tongue and swallowing muscles leading to severe difficulty with swallowing) - Spasticity so severe to inhibit transportation - Known multiple sulfatase deficiency - Presence of major congenital abnormality - Presence of known chromosomal abnormality and syndromes affecting psychomotor development - Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition - Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial - Use of any investigational product within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations - Received ERT with rhASA from any source |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Department of Pediatric Endocrinology and Neurology, Saint Vincent de Paul Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | European Leukodystrophy Association, Shire, Zymenex A/S |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of METAZYM on peripheral nerve function by electrophysiological studies (motor and sensory nerves conduction velocities) every 6 months; | every 6 months | No | |
Primary | Efficacy of METAZYM on peripheral nerve sulfatide storage and demyelination by nerve biopsy at baseline and week 26; | week 26 | No | |
Primary | Efficacy of METAZYM on functional capacity by assessing motor function (GMFM) every 6 months | every 6 months | No | |
Secondary | Efficacy of METAZYM on central nervous system involvement by evaluation of cognitive and neurological function, somatosensory and auditory evoked potentials, and brain MRI every 6 months; | every 6 months | No | |
Secondary | Safety profile of METAZYM by monitoring AE's, vital sign parameters and physical examination findings before each injection, as well as ECGs and routine clinical laboratory tests every 3 months. | every 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00383448 -
HSCT for High Risk Inherited Inborn Errors
|
Phase 2 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Active, not recruiting |
NCT04628364 -
The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
|
||
Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
Withdrawn |
NCT00639132 -
The Natural History of Metachromatic Leukodystrophy
|
||
Active, not recruiting |
NCT01801709 -
Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT00683189 -
Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy
|
N/A | |
Recruiting |
NCT02171104 -
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
|
Phase 2 | |
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Active, not recruiting |
NCT03392987 -
A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)
|
Phase 2 | |
Recruiting |
NCT02559830 -
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Completed |
NCT00004378 -
Stem Cell Transplantation (SCT) for Genetic Diseases
|
N/A | |
Active, not recruiting |
NCT04283227 -
OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)
|
Phase 3 | |
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Recruiting |
NCT04925349 -
Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
|
||
Active, not recruiting |
NCT00005900 -
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT01560182 -
Gene Therapy for Metachromatic Leukodystrophy (MLD)
|
Phase 1/Phase 2 | |
Completed |
NCT01586455 -
Human Placental-Derived Stem Cell Transplantation
|
Phase 1 |